Shots:

• Revance is in discussion with Mylan regarding whether Mylan plans to move forward or not with the biosimilar to BOTOX program. The expected decision date for Mylan is Apr 30- 2020 or thirty days from the date that Revance provides Mylan with certain deliverables regarding the program
• In Sept’2019- the companies amended their agreement to include an additional $5M to Revance in exchange for an extended decision period for Mylan to move forward with a development program. Revance has carried out additional characterization work and analysis for the benefit of the program
• In Feb 2018- the companies collaborated for development and regulatory approval of BOTOX's biosimilar. Revance received $25M as upfront and granted commercialization rights to Mylan in the US- EU and ROW

Click here ­to­ read full press release/ article | Ref: Revance | Image: Revance

Related News: Revance and Mylan Provide Updates on Development BOTOX (onabotulinumtoxinA) Biosimilar